Ted White - Jul 5, 2022 Form 4/A - Amendment Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
President and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Jul 5, 2022
Transactions value $
$15,750
Form type
4/A - Amendment
Date filed
2/21/2023, 03:08 PM
Date Of Original Report
Jul 5, 2022
Previous filing
Feb 25, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $15.8K +7.5K +34.14% $2.10 29.5K Jul 5, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 inadvertently listed the incorrect number of shares purchased by the Reporting Person. This represents the correct number of shares.